- Report
- August 2022
- 214 Pages
Global
From €4636EUR$4,799USD£3,964GBP
From €300EUR$333USD£266GBP
- Report
- February 2021
- 330 Pages
Global
From €2318EUR$2,400USD£1,982GBP
- Report
- May 2019
- 17 Pages
Global
From €604EUR$625USD£516GBP
€1207EUR$1,250USD£1,032GBP
- Clinical Trials
- November 2018
- 1100 Pages
Global
From €2898EUR$3,000USD£2,478GBP
- Report
- March 2024
- 94 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Report
- November 2021
- 747 Pages
Global
From €3864EUR$4,000USD£3,304GBP
- Report
- December 2020
- 98 Pages
Global
From €4347EUR$4,500USD£3,717GBP
Immunotoxins are a type of immune disorder drug that combines a toxin with an antibody or other targeting molecule to specifically target and destroy cells associated with an immune disorder. They are used to treat a variety of conditions, including cancer, autoimmune diseases, and infectious diseases. Immunotoxins are designed to target and destroy cells that are resistant to traditional treatments, such as chemotherapy and radiation. They are also used to reduce the side effects of other treatments.
Immunotoxins are typically administered intravenously or intratumorally, and can be used in combination with other treatments. They are generally well-tolerated and have few side effects. However, they can be expensive and may not be available in all countries.
Companies in the immunotoxins market include ImmunoGen, Inc., Seattle Genetics, Inc., and Merck KGaA. Show Less Read more